This is in regard to the captioned Buyback and in furtherance to our letter dated April 29, 2026 whereby we…
As filed · Buyback
What happened
FactThis is in regard to the captioned Buyback and in furtherance to our letter dated April 29, 2026 whereby we. submitted the Public Announcement pertaining to the captioned Buyback. In accordance with the Buyback Regulations, the Company has e-mailed the Letter of Offer to eligible.
Why it matters
CapitSignal interpretationA buyback returns cash by retiring shares, so the benefit to a holder depends on the price paid, how many of their shares are accepted, and what the stub is worth afterwards.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Order Book
DelayedWe are pleased with our FY25 performance, which underscores the strength of our strategy and execution.
Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Record date and acceptance ratio
- Promoter participation
- Cash left on the balance sheet afterwards
- Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting (management committed by FY29)
- Starting with a revenue base of Rs.53 crores, we are targeting Rs.10 crores EBITDA by year two post-integratio (management committed by FY27)
Evidence
- Jagsonpal Pharmaceuticals Limited has informed the Exchange about Buyback Letter of Offer(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- BUYBACK base 70; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%